AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Lonza says it has signed a deal to produce therapeutic monoclonal antibody Anthim for biopharmaceutical company Elusys Therapeutics (Pine Brook, NJ). Anthim, which is in late-stage development, can be used to treat anthrax infection. Lonza says it will provide process development services and manufacturing capacity, using its GS Gene Expression System, under the deal.
Elusys develops antibody therapeutics for treatment of …